drugset
drugset / Trial / NCT02268604

Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers

NCT02268604 ↗

Phase 1 Terminated 10 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to assess safety, pharmacodynamics and pharmacokinetics of BIIB 722 CL

Timeline

Start
2010-10
Primary completion
2010-10
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB 722 CL Unknown 200 mg Oral
Subject BIIB 722 CL Unknown 300 mg Oral
Subject BIIB 722 CL Unknown 450 mg Oral

Indications

No indication recorded.